WuXi Biologics ISIN: KYG970081173 Forum: Aktien User: Summer.76

Und?

https://www.fiercepharma.com/pharma/wuxi-biologics-plays-defense-after-draft-bill-brands-certain-chinese-biopharmas-security

N bis hen beruhigen lassen dann zugreifen

https://www.yicaiglobal.com/news/fact-check-wuxi-biologics-plunges-on-concerns-about-new-us-bill

https://www.prnewswire.com/news-releases/wuxi-biologics-announces-research-service-agreement-with-biontech-on-discovering-investigational-monoclonal-antibodies-for-developing-next-generation-therapeutic-product-candidates-302031587.html

https://www.fiercepharma.com/pharma/wuxi-biologics-stock-plummets-crdmo-trims-400m-revenue-projection

<font style="vertical-align: inherit;"><font style="vertical-align: inherit;">WUXI BIO: Umsatz und Gewinn unerwartet durch D- und M-Ende beeinträchtigt; </font><font style="vertical-align: inherit;">GPM und Wachstum werden im Jahr 2023 voraussichtlich mit Gegenwind konfrontiert sein</font></font> http://www.aastocks.com/en/mobile/news.aspx?newsid=NOW.1311318&newstype=61&newssource=AAFN

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1302977/

https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a231020.pdf UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF WUXI XDC CAYMAN INC.

WuXi Biologics Reports Solid 2023 Interim Results https://finance.yahoo.com/news/wuxi-biologics-reports-solid-2023-123000711.html Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth, Strong Momentum Continued Non-COVID Late-phase And Commercial Manufacturing Revenue Grew by 130.3% Y-o-Y "R" in CRDMO Accelerated to Extend Partnerships with Pharma Clients, Milestone Revenue Approximated US$60 Million Positive Free Cash Flow to Support Sustainable Growth Total Backlog Amounted to US$20,108 Million ...

https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/wuxi-biologics-cayman-incs-hkg2269-fundamentals-look-pretty

WuXi Biologics Hatches New Baby With ADC Drug Unit IPO https://seekingalpha.com/article/4618020-wuxi-biologics-hatches-new-baby-with-adc-drug-unit-ipo Summary • The drug outsourcing services company is spinning off its WuXi XDC unit, seizing on investor enthusiasm for a new generation of highly targeted ADC drugs. • WuXi XDC has filed for a Hong Kong IPO, calling itself the world’s second largest provider of contract services for bioconjugates such as antibody drug conjugates (ADCs). • The global market ADC drugs is expected to grow by 30% annually between 2022 and 2030. ...

WuXi Biologics: Spin-Off And New Projects In The Limelight (Rating Upgrade) https://seekingalpha.com/article/4618035-wuxi-biologics-spin-off-new-projects-in-limelight-rating-upgrade Summary • I have a favorable opinion of WuXi Biologics' planned spin-off, which could re-rate its valuations in a positive manner and help to accelerate the future growth of the spun-off business. • WXXWY's disclosures at its recent Investor Day regarding new project count have negative read-throughs for its near-term top-line growth prospects. • I upgrade my investment rating for WuXi Biologics to a Hold following a review of its spin-off plans, but WXXWY isn't a Buy as its business outlook is still unfavorable. ...

https://www.fiercepharma.com/pharma/wuxi-bio-telegraphs-spinoff-its-bioconjugate-subsidiary-xdc

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1275457/company-news/HK6

Was ist hier denn passiert?